Chest
Original ResearchAntithrombotic TherapyA Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation: The Euro Heart Survey
Section snippets
Materials and Methods
We used the large population database of the prospective Euro Heart Survey on AF, with data collected between 2003 and 2004. A detailed study outline of the Euro Heart Survey on AF at baseline5 and follow-up assessment18 has been previously described. In summary, 5,333 ambulatory and hospitalized patients with AF from 182 university, nonuniversity, and specialized hospitals among 35 member countries of the European Society of Cardiology were enrolled. Patients had to be ≥18 years of age and
Results
Of the 5,272 patients with AF in the Euro Heart Survey of AF who were discharged alive,5 3,456 (66%) patients without mitral valve stenosis or valvular surgery had 1-year follow-up status regarding major bleeding. The overall mean (SD) age was 66.8 (12.8) years, and the majority were men (59%). Fifty-three (1.5%) patients experienced a major bleed during the first year, including nine (17%) cases of intracerebral hemorrhage. The baseline demographic and clinical characteristics of the 3,456
Discussion
Using a derivation cohort based on the large, real-world population of the Euro Heart Survey on AF, we identified four independent risk factors of major bleeding within 1 year (prior major bleeding, age >65 years, clopidogrel use, and kidney failure). Incorporating these risk factors with other established risk factors from systematic reviews and multivariate analyses,11, 13, 19 we developed and tested a novel, user-friendly bleeding risk score, HAS-BLED, which demonstrated a good predictive
Conclusion
We propose a novel bleeding risk score, HAS-BLED, that provides an easy, practical tool to assess the individual bleeding risk of patients with AF. The use of this simple score may potentially support clinical decision making regarding antithrombotic therapy for stroke prevention.
Acknowledgments
Author contributions: Dr Pisters: contributed to statistical analyses, data interpretation, and drafting of the manuscript.
Dr Lane: contributed to drafting and revision of the manuscript.
Dr Nieuwlaat: contributed to statistical analyses, data interpretation, and drafting of the manuscript.
Dr de Vos: contributed to drafting and revision of the manuscript.
Dr Crijns: contributed to drafting and revision of the manuscript.
Dr Lip: contributed to study design and hypothesis, concept of the HAS-BLED
References (30)
- et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)
J Am Coll Cardiol
(2006) - et al.
Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation
J Am Coll Cardiol
(2005) - et al.
Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin
Am J Med
(1998) - et al.
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)
Am Heart J
(2006) - et al.
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
Lancet
(2009) - et al.
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birminigham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
Lancet
(2007) - et al.
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study
Stroke
(1991) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials
Arch Intern Med
(1994)- et al.
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
Ann Intern Med
(2007) - et al.
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation
Eur Heart J
(2005)
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study
Eur Heart J
Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence
Circulation
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation
JAMA
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation
Eur Heart J
Bleeding with anticoagulation therapy— who is at risk, and how best to identify such patients
Thromb Haemost
Cited by (3686)
A real-world multicenter study on left atrial appendage occlusion: The Italian multi-device experience
2024, IJC Heart and VasculatureBrain MRI microbleeds and risk of intracranial hemorrhage in atrial fibrillation patients: A Swedish case-control study
2024, Journal of Stroke and Cerebrovascular DiseasesExternal Validation of the OAC<sup>3</sup>-PAD Bleeding Score in a Nationwide Population of Patients Undergoing Invasive Treatment for Peripheral Arterial Disease
2024, European Journal of Vascular and Endovascular Surgery
Funding/Support: The Euro Heart Survey has as industry sponsors the main sponsor, AstraZeneca; major sponsor, Sanofi-Aventis; and sponsor, Eucomed. Funding institutions are the Austrian Heart Foundation, Austrian Society of Cardiology, French Federation of Cardiology, Hellenic Cardiological Society, Netherlands Heart Foundation, Portuguese Society of Cardiology, Spanish Cardiac Society, Swedish Heart and Lung Foundation, and individual centers.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).